Showing results (1411-1420 of 1,594) with videos related to
Sort By:
Pageof 160
Cancer Management and Research|December 11, 2019
A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung CancerMatthew B Schabath, Tapashi B Dalvi, Hongyue A Dai, et al.Journal of Ethnopharmacology|November 23, 2025
Mouse neuronal dendritic complexity and resilience to stress-induced depression in Drosophila melanogaster are enhanced by Withania somnifera alkaloidsRudranil Dutta, Helen Holvoet, Luke Marney, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2026
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung CancerJhanelle E Gray, Konstantin Laktionov, Sang-We Kim, et al.The Lancet. Oncology|March 17, 2018
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyMarina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2022
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung CancerAlberto A Chiappori, Ben Creelan, Tawee Tanvetyanon, et al.Journal of Neurosurgery|January 22, 2023
Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy aloneAmmoren E Dohm, Joseph D Tang, Matthew N Mills, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2024
The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLCJhanelle E Gray, Michael Schenker, Mehmet Ali Nahit Şendur, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2022
High Asymptomatic Carriage With the Omicron Variant in South AfricaNigel Garrett, Asa Tapley, Jessica Andriesen, et al.Cancer Immunology, Immunotherapy : CII|September 14, 2018
A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinomaJhanelle E Gray, Alberto Chiappori, Charlie C Williams, et al.Lung Cancer (Amsterdam, Netherlands)|July 24, 2020
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC studyMarina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, et al.Pageof 160